方盛制药(603998.SH):比索洛尔氨氯地平片获得药品注册证书

智通财经
Mar 04

智通财经APP讯,方盛制药(603998.SH)发布公告,2026年3月3日,公司全资子公司广东方盛健盟药业有限公司(简称“健盟药业”)收到国家药品监督管理局核准签发的《药品注册证书》,公司研发的比索洛尔氨氯地平片已获得药品批准文号,并可进行生产。

该药品适应症:作为高血压治疗的替代疗法,用于目前同时服用与复方制剂剂量相同的单药且血压控制良好的患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10